ArticleScience translational medicine2017
The druggable genome and support for target identification and validation in drug development.
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 625 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
625 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Genome-wide meta-analysis with 2,206,440 individuals identifies 322 novel risk loci for obesity.International journal of obesity (2005) · 2026Pooled it
- Dissecting the genetic and proteomic risk factors for delirium.Nature aging · 2026Pooled it
- Genome-Wide Meta-Analysis of Parkinson's Disease Associated Genetic Loci and Validation of Therapeutic Targets.Brain and behavior · 2025Pooled it
- Identification of genetically-supported new drug targets for osteomyelitis based on druggable genomes.Human genomics · 2025Pooled it
- Plasma proteomic analysis identified potential therapeutic targets for pulmonary arterial hypertension.iScience · 2026Article
- Genetic susceptibility, risk prediction, and druggable targets for oropharyngeal cancer: a UK Biobank study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Exploring causal associations between the plasma proteome and bone mineral density: a Mendelian randomization study.Endocrine connections · 2026Article
- A multi-omics and machine-learning framework reveals shared druggable targets for Alzheimer's disease and periodontitis and identifies amentoflavone and taraxerone as potential dual-action natural products.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Genetically supported targets and drug repurposing for sleep disorders: a Mendelian randomization systematic study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Genome-scale perturbation signatures from primary human CD4bioRxiv : the preprint server for biology · 2026Article
- Multi-Omics Genome-Wide to Explore the Formation and Development Targets for Intracranial Aneurysms.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Genetic Prioritization of Plasma Proteins Across Dementia Subtypes: A Proteome-Wide Mendelian Randomization and Bayesian Colocalization Analysis.Cellular and molecular neurobiology · 2026Article
- Identification of Pre-Diagnostic Protein Biomarkers for Liver Cirrhosis Based on Prospective Analysis of a Large-Scale Plasma Proteomics in the UK Biobank.Proteomics. Clinical applications · 2026Article
- Identification of CA2 as a potential candidate gene involved in the therapeutic effect of Huatan Huoxue decoction on polycystic ovary syndrome: An integrated study of network pharmacology, Mendelian randomization, and experimental validation.Journal of food and drug analysis · 2026Article
- Integrating multi-omics and mendelian randomization identifies therapeutic targets for Lichen Sclerosus: A druggable genome-wide study.Global medical genetics · 2026Article
- Using human proteomic and lipidomic to exploration drug target of bladder cancer.World journal of urology · 2026Article
- Article
- Proteomic Signatures of High-Risk Coronary Plaque Features and Incident Events.JACC. Basic to translational science · 2026Article
- Genome-wide association study identifies toll-like receptor four protein-mediated metabolic remodelling affecting gout pathogenesis.Journal of global health · 2026Observational
565 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Target identification (determining the correct drug targets for a disease) and target validation (demonstrating an effect of target perturbation on disease biomarkers and disease end points) are important steps in drug development. Clinically relevant associations of variants in genes encoding drug targets model the effect of modifying the same targets pharmacologically. To delineate drug development (including repurposing) opportunities arising from this paradigm, we connected complex disease- and biomarker-associated loci from genome-wide association studies to an updated set of genes encoding druggable human proteins, to agents with bioactivity against these targets, and, where there were licensed drugs, to clinical indications. We used this set of genes to inform the design of a new genotyping array, which will enable association studies of druggable genes for drug target selection and validation in human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.